Fig. 8
From: Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter
FGF7 derived from CAFs promotes tumor growth in vivo. A The tumor xenografts were photographed on the 31st day of the experiment. B Tumor volumes were recorded every five days. C Tumor weights were measured at the end of the experiment. D Immunohistochemistry (IHC) analysis (n = 5). DThe correlations between FGF7 and HIF-1α, FGFR2 IHC score in xenografts specimens were evaluated with Pearson correlation analysis (n = 5). E The correlations between FGF7 and ZEB1, Vimentin IHC score in xenografts specimens were evaluated with Pearson correlation analysis. (n = 5). F The correlations between FGF7 and E-cadherin, Ki-67 IHC score in xenografts specimens were evaluated with Pearson correlation analysis (n = 5). H–J The correlations between FGF7 and E-cadherin, ZEB1, FGFR2 IHC score in OC tissues were evaluated with Pearson correlation analysis. (n = 32). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001